Inscripta® Granted Patents for CRISPR Gene-Editing Systems
New data shows Inscripta’s MADzymes edit in mammalian cells
Read More
Inscripta® Releases New, Unique CRISPR Gene-Editing Enzyme; Free to Use for All Researchers
First Product Release from Inscripta’s Enzyme Engineering Platform
Read More
Muse bio appoints genomics industry expert, John Stuelpnagel, as Chairman of the Board of Directors
Muse bio, a privately-held company leading the development of next-generation genome engineering capabilities, today announced Dr. John Stuelpnagel, co-founder, first...
Read More
Nature Biotechnology paper details high-throughput, multiplexed CRISPR technology
Revolutionary technology licensed by Muse bio enables precise, genome-wide engineering
Read More
- 1
- 2